Innovations + Investments in Healthcare Summit 2015


AstraZenecaAstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit:

AstraZeneca RSS Channel

Title Filter      Display #  
# Article Title
1 AstraZeneca and Peregrine Pharmaceuticals to collaborate on immuno-oncology combination clinical trial
2 AstraZeneca and Heptares Therapeutics enter agreement to develop novel immuno-oncology treatments
3 MedImmune and Mirati Therapeutics partner on immuno-oncology combination in lung cancer
4 AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases
5 AstraZeneca further sharpens focus through agreement with Genzyme for rare disease medicine Caprelsa
6 AstraZeneca completes agreement with Tillotts Pharma for Entocort
7 IRESSA approved by US FDA for first-line treatment of patients with advanced EGFR mutation-positive non-small cell lung cancer
8 AstraZeneca sharpens focus on main therapy areas through agreement with gastroenterology specialist Tillotts Pharma
9 AstraZeneca and Lilly to collaborate on Immuno-oncology combination clinical trial in solid tumours
10 AstraZeneca provides update on brodalumab development programme
11 AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden
12 AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits
13 FDA grants Priority Review for potential new indication for Brilinta
14 AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology
15 AstraZeneca and PatientsLikeMe announce global research collaboration
16 AstraZeneca joins Genomics England consortium
17 AstraZeneca to collaborate with the Harvard Stem Cell Institute in diabetes
18 AstraZeneca announces positive Phase III top-line results for PT003 from PINNACLE 1 and PINNACLE 2 studies in COPD
19 PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack
20 AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
World Pharma News RSS Channel
Subscribe to World Pharma News by Email

Follow/Join us on:   Facebook   Twitter   XING   LinkedIn   Google Groups    FeedBurner

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]